BioNTech SE American Depositary Share (BNTX)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with the business, not the stock chart. BioNTech earned its fame from BNT162, the COVID vaccine, but that revenue stream is clearly normalizing. Revenue growth is -35.39% and profit growth -27.92%, and in fiscal Q2 2026 it reported $105.6M of revenue with a $820.8M net loss. That is a company spending heavily to create future oncology products while its current commercial engine shrinks. The pipeline—Gotistobart, Pumitamig, Trastuzumab pamirtecan—could be valuable, but I cannot yet see durable earnings power from the filed numbers. The balance sheet is a real strength. Debt/equity is 0.02, Altman Z-Score is 8.06, and trailing free cash flow is $444.7M, a 1.6% FCF yield. But the income statement is weak: ROE is -9.30%, ROCE is -5.41%, and the Piotroski F-Score is 3/9. At the 2026-10-13 close of $89.01, the FairStock-calculated P/B is 1.09 and P/E is -11.57. Paying roughly book value for a loss-making biotech is not obviously expensive if the pipeline succeeds, but it is not a Graham bargain either, because book value here is not a stable earnings asset. The FairStock Score is 56/100, and the computed Lynch category is 'none' due to insufficient filed annual results. I would need evidence of pipeline approval, revenue stabilization, and narrowing losses before calling this a high-quality compounder. Until then, it is a speculative research bet, not a proven business.

In plain English: BioNTech is a German healthcare company that develops vaccines and immunotherapies, best known for its COVID-19 vaccine, and is working on cancer treatments. The business looks weak right now: sales have fallen sharply and it is losing money, partly because COVID revenue has faded. The share price is close to the value of the company's net assets on its books, so it does not look wildly expensive, but profits and sales are not yet supporting the valuation.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer